Pharma Journalist -

SMi Reports: Registration is open for SMi’s inaugural AI in Drug Discovery conference taking place in London in March 2020. SMi is delighted to announce the highly anticipated AI in…
Read More...

SMi has released an exclusive interview with industry expert Richard Marsden, CEO of Synairgen, ahead of the upcoming Respiratory Drug Delivery conference this December. Respiratory…
Read More...

HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve…
Read More...

Shifting the paradigm from targeting protein to targeting RNA requires rethinking several aspects of drug discovery including target selection, lead discovery, assays to support lead…
Read More...

Panel Discussion: Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities At this year’s 2nd RNA-Targeted Drug Discovery Summit (December 2-4, Boston), an expert…
Read More...

The recent expansion of the RNA space has resulted in the emergence of many specialised biotechs, particularly in North America and Europe. Investment ranges from $30-70mil across the…
Read More...

Alvogen and Zentiva Group a.s announced that Alvogen has signed a definitive agreement to sell its Central and Eastern European business to Zentiva, for an undisclosed amount.…
Read More...

Vertex Pharmaceuticals Incorporated announced an access agreement with NHS England for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these…
Read More...

Novartis announced that the European Commission (EC) has approved a label update for the up-titration of Cosentyx (secukinumab) to 300 mg for patients with active ankylosing spondylitis…
Read More...

Allergan plc announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX for the treatment of pediatric…
Read More...